Document Type
Article
Publication Date
10-22-2025
Identifier
DOI: 10.1172/jci.insight.193975
Abstract
Bronchopulmonary dysplasia (BPD) remains a debilitating disease in premature infants. The chronic pathogenesis of BPD with complex prenatal and postnatal programming challenges attempts at precisely defining or treating disease. While existing BPD definitions categorize disease severity, a lack of consideration of disease heterogeneity and endotypes has contributed to the failure of clinical trials to improve BPD outcomes. Recent studies have used advanced lung imaging techniques, echocardiography, and lung function tests to identify airway, parenchymal, and vascular BPD endotypes. These endotypes carry different prognoses and require endotype-specific treatment strategies to optimize infant outcomes. In this Review, we focus on the pathogenic mechanisms that specify individual BPD endotypes and discuss how combining biomarkers, functional studies, and artificial intelligence-based characterization of endotypes can inform precision therapies for BPD.
Journal Title
JCI Insight
Volume
10
Issue
20
MeSH Keywords
Humans; Bronchopulmonary Dysplasia; Infant, Premature; Infant, Newborn; Precision Medicine; Lung; Biomarkers
PubMed ID
41122965
Keywords
Bronchopulmonary Dysplasia; Precision Medicine; Lung; Biomarkers
Recommended Citation
Sharma M, Akangire G, Hillman NH, Manimtim WM, Attard MI, Sampath V. Defining endotypes of bronchopulmonary dysplasia in preterm infants to improve precision-based therapies. JCI Insight. 2025;10(20):e193975. Published 2025 Oct 22. doi:10.1172/jci.insight.193975
Comments
This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
Publisher's Link: https://insight.jci.org/articles/view/193975